|
🐜
|
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
18 auth.
J. Regula,
Peter Lundh von Leithner,
R. Foxton,
V. Barathi,
C. Cheung,
Sai Bo Bo Tun,
Yeo Sia Wey,
Daiju Iwata,
M. Dostálek,
J. Moelleken,
...
K. Stubenrauch,
E. Nogoceke,
G. Widmer,
P. Strassburger,
M. Koss,
C. Klein,
D. Shima,
G. Hartmann
|
7 |
2016 |
7
🐜
|
|
🐜
|
Combined Inhibition of Tumor Necrosis Factor α and Interleukin‐17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody
14 auth.
Jens A. A. Fischer,
A. Hueber,
Stacy L. Wilson,
Margarete Galm,
W. Baum,
C. Kitson,
Johannes Auer,
Stefan H. Lorenz,
J. Moelleken,
M. Bader,
...
A. Tissot,
Seng-Lai Tan,
S. Seeber,
G. Schett
|
7 |
2015 |
7
🐜
|
|
🐜
|
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
18 auth.
J. Regula,
Peter Lundh von Leithner,
R. Foxton,
V. Barathi,
Chui Ming Gemmy Cheung,
Sai Bo Bo Tun,
Yeo Sia Wey,
Daiju Iwata,
M. Dostálek,
J. Moelleken,
...
K. Stubenrauch,
E. Nogoceke,
G. Widmer,
P. Strassburger,
M. Koss,
C. Klein,
D. Shima,
G. Hartmann
|
6 |
2017 |
6
🐜
|
|
🦁
|
Differential localization of coatomer complex isoforms within the Golgi apparatus
11 auth.
J. Moelleken,
Jörg Malsam,
M. Betts,
A. Movafeghi,
I. Reckmann,
Ingrid Meißner,
...
A. Hellwig,
R. Russell,
T. Söllner,
B. Brügger,
F. Wieland
|
6 |
2007 |
6
🦁
|
|
🐜
|
Differential roles of ArfGAP1, ArfGAP2, and ArfGAP3 in COPI trafficking
7 auth.
C. Weimer,
R. Beck,
Priska Eckert,
I. Reckmann,
J. Moelleken,
B. Brügger,
...
F. Wieland
|
6 |
2008 |
6
🐜
|
|
🐬
|
The Tyrosine Kinase Pyk2 Regulates Arf1 Activity by Phosphorylation and Inhibition of the Arf-GTPase-activating Protein ASAP1*
Anamarija Kruljac-Letunic,
J. Moelleken,
A. Kallin,
F. Wieland,
A. Blaukat
|
5 |
2003 |
5
🐬
|
|
🐜
|
Discriminatory aptamer reveals serum response element transcription regulated by cytohesin-2.
7 auth.
M. Theis,
A. Knorre,
Bettina Kellersch,
J. Moelleken,
F. Wieland,
W. Kolanus,
...
M. Famulok
|
5 |
2004 |
5
🐜
|
|
🐜
|
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
18 auth.
J. Regula,
Peter Lundh von Leithner,
R. Foxton,
V. Barathi,
Gemmy Cheung Chui Ming,
S. B. B. Tun,
Yeo Sia Wey,
Daiju Iwata,
M. Dostálek,
J. Moelleken,
...
K. Stubenrauch,
E. Nogoceke,
G. Widmer,
P. Strassburger,
M. Koss,
C. Klein,
D. Shima,
G. Hartmann
|
4 |
2019 |
4
🐜
|
|
🦁
|
GingisKHAN™ protease cleavage allows a high-throughput antibody to Fab conversion enabling direct functional assessment during lead identification of human monoclonal and bispecific IgG1 antibodies
9 auth.
J. Moelleken,
Manuel Endesfelder,
Christian Gassner,
Sabine Lingke,
Simone Tomaschek,
O. Tyshchuk,
...
S. Lorenz,
Ulrike Reiff,
Michael Mølhøj
|
4 |
2017 |
4
🦁
|
